Gilead Sciences is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative therapeutics to address significant unmet medical needs, particularly in the fields of antiviral therapies, oncology, and inflammation. The company is well-known for its advancements in treatments for diseases such as HIV, hepatitis C, and influenza, while also expanding its portfolio to include oncology products and therapies for other serious conditions. Gilead is committed to improving patient outcomes through its cutting-edge science and collaborative efforts, working to develop medicines that have both transformative efficacy and address critical health challenges on a global scale. Read More
American households are bracing for a significant financial hit as a wave of tariff-induced inflation sweeps across critical consumer goods and services. From the family car to essential baby products, and even the cost of staying healthy, prices are already on an upward trajectory or are poised for substantial hikes.
The American economy is facing a new headwind as weakening wage growth begins to temper consumer spending, raising concerns about the pace and sustainability of the broader economic recovery. Recent data indicates a moderation in the rate at which workers' earnings are increasing, a trend that, while potentially helping to
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antiviral drugs designed to resist viral escape, announced it will present at the Life Science Executive Partnering (LSX) World Congress 2025 in Boston on Wednesday, Sept. 17, at 12:30 p.m.
On Monday, the tech-heavy Nasdaq Composite climbed to a new high despite the ongoing uncertainty regarding the state of the U.S. economy and the rate outlook.
The global economy is currently grappling with a projected deceleration in GDP growth, a situation severely exacerbated by an unprecedented escalation of U.S. tariffs. These twin forces are creating a potent cocktail of stagflationary pressures, threatening to disrupt corporate supply chains, erode investor confidence, and reshape the landscape of
Gilead Sciences, Inc. (Nasdaq: GILD) today announced a partnership with the U.S. State Department and the United States President’s Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir—Gilead's twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). This is a key component of Gilead’s larger coordinated efforts, now bringing together the resources and expertise of both PEPFAR and the Global Fund, to further advance access to lenacapavir for PrEP for up to two million people over three years in countries supported by both organizations.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of Choose U™, a new campaign that spotlights the multifaceted experiences of people living with HIV globally. The timing of the campaign launch coincides with the convening of the 2025 United States Conference on HIV/AIDS (USCHA) taking place September 4-7 in Washington DC, which will center on the theme of aging with HIV.
Gilead Sciences (Nasdaq: GILD) today celebrates the groundbreaking of its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the company’s Foster City headquarters. This milestone marks continued momentum in Gilead’s multi-year strategy to drive growth and scientific leadership across virology, oncology, and inflammation, increasingly built on growing biologics capabilities. It is part of Gilead’s planned $32 billion investment in U.S. innovation through 2030. This investment is projected to generate more than $43 billion in economic value nationwide, strengthening America’s biopharmaceutical leadership while fueling high-quality jobs, research, and domestic manufacturing.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry’s return was flat while the S&P 500 climbed by 9.7%.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo® (lenacapavir)—the company’s twice-yearly injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition risk who weigh at least 35kg. Yeytuo is the first and only twice-yearly PrEP option to be approved for use in the European Union’s 27 member states, as well as Norway, Iceland and Liechtenstein.
Markets dipped Thursday as Coty issued a dismal forecast, Gilead faced headwinds with its new HIV drug, and investors turned cautious ahead of Fed Chair Powell’s Jackson Hole speech. Solid PMI data complicated the interest rate outlook, stalling hopes for imminent rate cuts.
Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD)
fell 3.5% in the morning session after reports that CVS Health will not be adding the company's new HIV prevention drug, Yeztugo, to its commercial insurance plans for now.
Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access.
